The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

《European Journal Of Clinical Pharmacology》是一本由SPRINGER HEIDELBERG出版商出版的专业医学期刊，该刊创刊于1968年，刊期Monthly，该刊已被国际权威数据库SCI、SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 3区，小类学科：药学 3区；在JCR（Journal Citation Reports）分区等级为Q3。该刊发文范围涵盖药学等领域，旨在及时、准确、全面地报道国内外药学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为3.064，平均审稿速度一般,3-8周。